ISSN 2415-3060 (print), ISSN 2522-4972 (online)
  • 11 of 25
УЖМБС 2022, 7(4): 76–82
Clinical Medicine

Influence of L-Arginine on the Clinical Course and Hemodynamic Parameters in Patients with Coronary Artery Disease on the Background of Anemic Syndrome in Middle-Aged and Older Patients

Khanyukov O. O. 1, Zayats I. O. 2

The purpose of the study was to evaluate hemodynamic changes in middle-aged and older patients with coronary artery disease and anemia, against the background of standard therapy, as well as in combination with L-arginine. Materials and methods. 53 patients (35 women and 18 men) with stable ischemic heart disease and mild to moderate anemia (mean age 73.1 ± 1.2 years old) were examined. Among them, there were 24 (45.3%) patients with HF I, 21 (39.6%) patients with HF 2A, and 8 (15.1%) patients with HF 2B. The control subgroup (subgroup 1) consisted of 24 patients who received standard therapy for coronary artery disease and anemia. The remaining 29 people, in addition to standard therapy, additionally received L-arginine according to the scheme and made up the 2nd subgroup of the study. The follow-up period for patients was 6 months. An anamnesis was collected from all patients, the clinical picture of the disease was assessed, blood pressure and heart rate were measured, clinical and biochemical blood tests were studied, ECG and ECHO-CG were recorded. The effect of treatment with iron preparations was assessed by the dynamics of iron metabolism parameters. In the course of the ECHO-CG study, the main structural-geometric and functional parameters of the left ventricle were determined. Results and discussion. Under the influence of standard therapy and an increase in hemoglobin levels to normal levels (from 114.8 ± 1.4 g/l to 131.9 ± 1.1 g/l in the first subgroup; from 112.3 ± 2.1 g/l to 140.0 ± 1.3 g/l in the second subgroup (p<0.001 between subgroups after treatment) [17], complaints of general weakness, shortness of breath and palpitations decreased and the general condition of patients improved (blood pressure, heart rate, respiratory rate parameters normalized; there was a decrease or elimination of edema) in both clinical groups. But in patients who additionally received L-arginine, the intensity of manifestations of general weakness and palpitations were significantly less (p<0.001 and p<0.05 between subgroups). Against the background of standard therapy, symptoms such as dyspnea, edema, and pain in the heart area also decreased in both subgroups, but the effect of L-arginine on these symptoms was more noticeable. According to the results of the ECHO-CG study, in patients with coronary artery disease and anemia, a statistically significant recovery of structural and geometric parameters of the myocardium was observed: a decrease in end-diastolic and end-systolic volume and an increase in myocardial contractility in both subgroups, however, against the background of additional intake of L-arginine, the dynamics of indicators was more expressed; regression of signs of left ventricle hypertrophy. Conclusion. The results of the study showed the positive effect of L-arginine on cardiac remodeling and the clinical condition of middle-aged and older patients. Treatment with L-arginine did not cause side effects and did not require discontinuation of the drug

Keywords: cardiovascular disease, coronary artery disease, anemia, L-arginine

Full text: PDF (Ukr) 338K

  1. Roth GA, Mensah GA, Johnson CO, Addolorato G, Ammirati E, Baddour LM, et al. Global Burden of Cardiovascular Diseases and Risk Factors, 1990–2019: Update From the GBD 2019 Study. J Am Coll Cardiol. 2020 Dec 22;76(25):2982-3021. PMID: 33309175. PMCID: PMC7755038. doi: 10.1016/j.jacc.2020.11.010
  2. Khan MA, Hashim MJ, Mustafa H, Baniyas MY, Al Suwaidi SKBM, AlKatheeri R, et al. Global Epidemiology of Ischemic Heart Disease: Results from the Global Burden of Disease Study. Cureus. 2020;12(7):e9349. PMID: 32742886. PMCID: PMC7384703. doi:10.7759/cureus.9349
  3. Meng H, Wang Y, Ruan J, Chen Y, Wang X, Zhou F, et al. Decreased Iron Ion Concentrations in the Peripheral Blood Correlate with Coronary Atherosclerosis. Nutrients. 2022 Jan 13;14(2):319. PMID: 35057500. PMCID: PMC8781549. doi: 10.3390/nu14020319
  4. Stahl-Gugger A, de Godoi Rezende Costa Molino C, Wieczorek M, Chocano-Bedoya PO, Abderhalden LA, Schaer DJ, et al.; DO-HEALTH Research Group. Prevalence and incidence of iron deficiency in European community-dwelling older adults: an observational analysis of the DO-HEALTH trial. Aging Clin Exp Res. 2022 Mar 18. PMID: 35304704. doi: 10.1007/s40520-022-02093-0
  5. Martens P, Verbrugge FH, Nijst P, Dupont M, Mullens W. Limited contractile reserve contributes to poor peak exercise capacity in iron-deficient heart failure. Eur J Heart Fail. 2018 Apr;20(4):806-808. PMID: 28925093. doi: 10.1002/ejhf.938
  6. Lanser L, Fuchs D, Scharnagl H, Grammer T, Kleber ME, März W, et al. Anemia of Chronic Disease in Patients With Cardiovascular Disease. Front Cardiovasc Med. 2021 Aug 12;8:666638. PMID: 34458328. PMCID: PMC8387678. doi: 10.3389/fcvm.2021.666638
  7. Rymer JA, Rao SV. Anemia and coronary artery disease: pathophysiology, prognosis, and treatment. Coron Artery Dis. 2018 Mar;29(2):161-167. PMID: 29280914. doi: 10.1097/MCA.0000000000000598
  8. González-D'Gregorio J, Miñana G, Núñez J, Núñez E, Ruiz V, García-Blas S, et al. Iron deficiency and long-term mortality in elderly patients with acute coronary syndrome. Biomark Med. 2018 Sep;12(9):987-999. PMID: 30043644. doi: 10.2217/bmm-2018-0021
  9. Ahmad A, Dempsey SK, Daneva Z, Azam M, Li N, Li PL, et al. Role of Nitric Oxide in the Cardiovascular and Renal Systems. Int J Mol Sci. 2018 Sep 3;19(9):2605. PMID: 30177600. PMCID: PMC6164974. doi: 10.3390/ijms19092605
  10. Yalovenko MI, Khaniukov OO. Vybir optymalnoi medykamentoznoi terapii u khvorykh z fibryliatsiieiu peredserd i komorbidnoiu palohiieiu [The choice of optimal drug therapy in patients with atrial fibrillation and comorbid pathology]. Morphologia. 2018;12(4):104-115. [Ukrainian]. doi: 10.26641/1997-9665.2018.4.104-115
  11. Totzeck M, Hendgen-Cotta UB, Rassaf T. Nitrite-Nitric Oxide Signaling and Cardioprotection. Adv Exp Med Biol. 2017;982:335-346. PMID: 28551796. doi: 10.1007/978-3-319-55330-6_18
  12. Tejero J, Shiva S, Gladwin MT. Sources of Vascular Nitric Oxide and Reactive Oxygen Species and Their Regulation. Physiol Rev. 2019 Jan 1;99(1):311-379. PMID: 30379623. PMCID: PMC6442925. doi: 10.1152/physrev.00036.2017
  13. Wu G, Meininger CJ, McNeal CJ, Bazer FW, Rhoads JM. Role of L-Arginine in Nitric Oxide Synthesis and Health in Humans. Adv Exp Med Biol. 2021;1332:167-187. PMID: 34251644. doi: 10.1007/978-3-030-74180-8_10
  14. Najafi H, Abolmaali SS, Heidari R, Valizadeh H, Jafari M, Tamaddon AM, et al. Nitric oxide releasing nanofibrous Fmoc-dipeptide hydrogels for amelioration of renal ischemia/reperfusion injury. J Control Release. 2021 Sep 10;337:1-13. PMID: 34271033. doi: 10.1016/j.jconrel.2021.07.016
  15. Cziráki A, Lenkey Z, Sulyok E, Szokodi I, Koller A. L-Arginine-Nitric Oxide-Asymmetric Dimethylarginine Pathway and the Coronary Circulation: Translation of Basic Science Results to Clinical Practice. Front Pharmacol. 2020 Sep 29;11:569914. PMID: 33117166. PMCID: PMC7550781. doi: 10.3389/fphar.2020.569914
  16. Liu C, Liang MC, Soong TW. Nitric Oxide, Iron and Neurodegeneration. Front Neurosci. 2019 Feb 18;13:114. PMID: 30833886. PMCID: PMC6388708. doi: 10.3389/fnins.2019.00114
  17. Khaniukov OO, Zaiats IO. Vplyv donatoriv oksydu azotu na klinichnyi perebih ishemichnoi khvoroby sertsia z suputnoiu anemiieiu [Influence of Nitric Oxide Donors on the Clinical Course of Coronary Heart Disease with Concomitant Anemia]. Ukr Zh Med Biol Sport. 2022;3(37):192-199. [Ukrainian]. doi: 10.26693/jmbs07.03.192